Agomab reports positive topline data from STENOVA open-label extension of ontunisertib in fibrostenosing Crohn’s disease

• Agomab Therapeutics NV reported positive topline results from a long-term extension of its mid-stage ontunisertib study in fibrostenosing Crohn’s disease.
• Patients generally maintained disease control over extended treatment, with few procedure-related interventions and no reported surgeries.
• Safety and tolerability remained favorable over the longer follow-up, supporting continued development of the drug candidate.
• Detailed results have not yet been presented; a conference presentation is planned for a future scientific meeting.
• Data support starting the global NOV-ERA Phase 2b trial in the coming months, testing multiple dose levels against placebo in about 320 patients.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Agomab Therapeutics NV published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610010630PRIMZONEFULLFEED1001275637) on October 01, 2026, and is solely responsible for the information contained therein.